Jose-maria Moraleda

Murcia, MU, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma.

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma.

Journal: Blood

Published: April 16, 2024

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Journal: Haematologica

Published: August 25, 2023

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.

Journal: Nature communications

Published: November 25, 2022

Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.

Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.

Journal: Histopathology

Published: February 21, 2022

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.

Journal: Blood advances

Published: December 03, 2021

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.

Journal: Blood

Published: May 04, 2020

R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.

R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.

Journal: Cancer medicine

Published: April 28, 2020

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 27, 2019

Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma.

Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: October 17, 2018

IL-4 Up-Regulates MiR-21 and the MiRNAs Hosted in the CLCN5 Gene in Chronic Lymphocytic Leukemia.

IL-4 Up-Regulates MiR-21 and the MiRNAs Hosted in the CLCN5 Gene in Chronic Lymphocytic Leukemia.

Journal: PloS one

Published: November 18, 2014

The gene expression response of chronic lymphocytic leukemia cells to IL-4 is specific, depends on ZAP-70 status and is differentially affected by an NFκB inhibitor.

The gene expression response of chronic lymphocytic leukemia cells to IL-4 is specific, depends on ZAP-70 status and is differentially affected by an NFκB inhibitor.

Journal: PloS one

Published: June 16, 2014

Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients.

Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients.

Journal: Leukemia & lymphoma

Published: June 11, 2014

Showing 1-12 of 12

Last Updated: 09/26/2026